dosulepin
Trade name: Prothiaden
Dosulepin, also known as dothiepin and sold under the brand name Prothiaden among others, is a tricyclic antidepressant (TCA) which is used in the treatment of depression. Dosulepin was once the most frequently prescribed antidepressant in the United Kingdom, but it is no longer widely used due to its relatively high toxicity in overdose without therapeutic advantages over other TCAs. It acts as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also has other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Apr 5, 2017 (NCT03126188)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- Serotonin 1a (5-HT1a) receptorANTAGONIST
HTR1A antagonist
- Norepinephrine transporterINHIBITOR
Norepinephrine transporter inhibitor
Also inhibits the neuronal uptake of dopamine and has other effects (e.g. anticholinergic, antihistaminic and anti-α1 adrenergic effects)
- Serotonin transporterINHIBITOR
Serotonin transporter inhibitor
Also inhibits the neuronal uptake of dopamine and has other effects (e.g. anticholinergic, antihistaminic and anti-α1 adrenergic effects)
Chemistry & pharmacology
SMILES
CN(C)CC/C=C1\c2ccccc2CSc2ccccc21- Mol. weight
- 295.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1492500 ↗
- WikipediaDosulepin ↗
- ChEMBLCHEMBL1711280 ↗
- ChEMBLCHEMBL108947 ↗
Also known as
- 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
- 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
- (3e)-3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethylpropan-1-amine
- (3e)-3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethylpropan-1-amine
- dosulepin
- dosulepin
- dosulepin
- dosulepin
- dosulepin
- dosulepin
- dosulepin
- dosulepin
- dosulepin
- dosulepina
- dosulepina
- dosulepine
- dosulépine
- dosulépine
- dosulepin hcl
- dosulepin hcl
- dosulepin hcl
- dosulepin hydrochloride
- dosulepinum
- dosulepinum
- dothapax 25
- dothapax 75
- dothiepin
- dothiepin
- dothiepin
- dothiepin
- dothiepin hcl
- dothiepin hcl
- dothiepin hcl
- dothiepin hydrochloride
- dothiepin hydrochloride
- dothiepin hydrochloride
- ken-pro
- prepadine
- prothiaden
- prothiaden
- prothiaden
- prothiadene
- thaden
- trans-dothiepin
- trans-dothiepin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06803485 | Phase 4 | Mar 11, 2025 | All India Institute of Medical Sciences |
| NCT03126188 | Phase 4 | Apr 5, 2017 | All India Institute of Medical Sciences |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| All India Institute of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2017 |